Targeting FA synthesis by inhibiting FASN, ACLY, and ACSS2 has been the subject of numerous preclinical and several clinical studies in various cancers, including breast, lung, colon, prostate, and bladder [58]. The gene discussed is ACSS2; the disease is cancer.